InspireMD

InspireMD Liabilities

The The Liabilities of InspireMD (NSPR) as of Oct 16, 2026 is 14.20 M USD. In the previous year, The Liabilities was 10.72 M USD — a change of 32.48% (higher).

Liabilities

14.20 MUSD

YoY

32.48%

Last updated:

In 2025, InspireMD's total liabilities amounted to 14.20 M USD, a 32.48% difference from the 10.72 M USD total liabilities in the previous year.

The InspireMD Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
3.53 M USD
Jan 1, 2019
4.50 M USD
Jan 1, 2020
5.61 M USD
Jan 1, 2021
6.18 M USD
Jan 1, 2022
7.26 M USD
Jan 1, 2023
8.14 M USD
Jan 1, 2024
10.72 M USD
Jan 1, 2025
14.20 M USD
The InspireMD Liabilities history
YEARLiabilitiesYoY
14.20 MUSD+32.48%
10.72 MUSD+31.68%
8.14 MUSD+12.15%
7.26 MUSD+17.48%
6.18 MUSD+10.08%
5.61 MUSD+24.84%
4.50 MUSD+27.57%
3.53 MUSD+4.29%
3.38 MUSD-37.00%
5.37 MUSD-38.50%
8.72 MUSD-38.76%
14.25 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InspireMD Stock analysis

What does InspireMD do? InspireMD Inc, listed on the stock market with ticker NSPR and ISIN US45779A8466, is a medical device company based in Tel Aviv-Yafo, Israel. The company operates within the Health Care sector, specifically in the Health Care industry. InspireMD has 127 employees and went public through an IPO on April 12, 2013. Its website is http://www.inspiremd.com/. The company focuses on developing and commercializing stent platform technology for treating complex vascular and coronary diseases. InspireMD's MicroNet is a micron mesh sleeve designed to wrap around a stent, providing embolic protection during stenting procedures. The company also offers the CGuard carotid embolic prevention system, which integrates MicroNet with a self-expandable nitinol stent for carotid artery applications. Additionally, InspireMD markets the MGuard Prime Embolic Protection System, a bare-metal cobalt-chromium stent, for coronary disease treatment in the European Union. The MGuard Prime EPS is also intended for use in patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft coronary interventions. The company is developing a neurovascular flow diverter called NGuard, an endovascular device. InspireMD's technology aims to enhance safety and efficacy in vascular and coronary interventions by preventing embolic events during stent placement. InspireMD is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing InspireMD's Liabilities

InspireMD's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating InspireMD's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing InspireMD's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

InspireMD's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in InspireMD’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about InspireMD stock

The Liabilities of InspireMD is 14.20 M USD in 2025.

The Liabilities of InspireMD changed from 10.72 M USD to 14.20 M USD, representing a 32.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities InspireMD since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's InspireMD historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — InspireMD

All Key Metrics — InspireMD